Inhibition of NOTCH1 may not only induce mesenchymal-epithelial transition (MET, namely, the reverse process of EMT), but also suppress the invasion and metastasis of various types of cancer cells [43–46], suggesting that NOTCH1 inhibitors may be useful for treating patients with metastatic cancers, such as advanced stage NSCLC, for which metastasis is the main cause of patient death. This evidence concerns the gene NOTCH1 and non-small cell lung carcinoma.